Evaluating the susceptibility to ceftazidime-avibactam in clinical isolates of Klebsiella pneumoniae and Pseudomonas aeruginosa recovered from an apex medical hospital in north India.
{"title":"Evaluating the susceptibility to ceftazidime-avibactam in clinical isolates of <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> recovered from an apex medical hospital in north India.","authors":"Nargis Bali, Tufail Ahmed, Biswajyoti Borkakoty, Roseleen Bali, Anjum Ara Mir, Zubair Teli, Qounser Nisar, Tantray Faisal","doi":"10.18502/ijm.v17i2.18385","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objectives: </strong>We assessed the susceptibility of ceftazidime+avibactam (CZA/AVI) in <i>Klebsiella pneumoniae</i> and <i>Pseudomonas aeruginosa</i> isolated from intensive care units of our hospital.</p><p><strong>Materials and methods: </strong>Clinical samples from Jan 2022 to Dec 2023 at SKIMS Soura, were processed for the recovery of <i>K. pneumoniae</i> and <i>P. aeruginosa</i>. Susceptibility testing was done by disc diffusion (DD) method and minimum inhibitory concentration (MIC) for CZA/AVI and meropenem was assessed using E-test strips. Categorical agreement (CA), very major errors (VME), major errors (ME) and minor errors (mE) between DD and MIC were measured. Statistical analyses were performed using SPSS version 22.0.</p><p><strong>Results: </strong>A total of 111 <i>K. pneumoniae</i> and 81 <i>P. aeruginosa</i> were part of the study. Of these, 56.8% <i>K. pneumoniae</i> and 45.7% <i>P. aeruginosa</i> isolates were susceptible to CZA/AVI. MIC of CZA/AVI for <i>K. pneumoniae</i> ranged from 0.125 to ≥ 256 μg/ml and for <i>P. aeruginosa</i> it ranged from 0.032 to 128 μg/ml. CA was 97.29% between DD and E-Test for CZA/AVI in <i>K. pneumoniae</i> isolates, with a ME of 2.70%. For <i>P. aeruginosa</i> CA between DD and E-Test for CZA/AVI was 98.76% with a VME of 1.23%. MIC values of meropenem were higher than CZA/AVI even in sensitive isolates.</p><p><strong>Conclusion: </strong>CZA/AVI shows good in-vitro activity against clinical isolates of <i>K. pneumoniae</i> and <i>P. aeruginosa</i> and can be part of empirical therapy for treating infections caused by these bacteria.</p>","PeriodicalId":14633,"journal":{"name":"Iranian Journal of Microbiology","volume":"17 2","pages":"253-260"},"PeriodicalIF":1.3000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12053426/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Iranian Journal of Microbiology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18502/ijm.v17i2.18385","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background and objectives: We assessed the susceptibility of ceftazidime+avibactam (CZA/AVI) in Klebsiella pneumoniae and Pseudomonas aeruginosa isolated from intensive care units of our hospital.
Materials and methods: Clinical samples from Jan 2022 to Dec 2023 at SKIMS Soura, were processed for the recovery of K. pneumoniae and P. aeruginosa. Susceptibility testing was done by disc diffusion (DD) method and minimum inhibitory concentration (MIC) for CZA/AVI and meropenem was assessed using E-test strips. Categorical agreement (CA), very major errors (VME), major errors (ME) and minor errors (mE) between DD and MIC were measured. Statistical analyses were performed using SPSS version 22.0.
Results: A total of 111 K. pneumoniae and 81 P. aeruginosa were part of the study. Of these, 56.8% K. pneumoniae and 45.7% P. aeruginosa isolates were susceptible to CZA/AVI. MIC of CZA/AVI for K. pneumoniae ranged from 0.125 to ≥ 256 μg/ml and for P. aeruginosa it ranged from 0.032 to 128 μg/ml. CA was 97.29% between DD and E-Test for CZA/AVI in K. pneumoniae isolates, with a ME of 2.70%. For P. aeruginosa CA between DD and E-Test for CZA/AVI was 98.76% with a VME of 1.23%. MIC values of meropenem were higher than CZA/AVI even in sensitive isolates.
Conclusion: CZA/AVI shows good in-vitro activity against clinical isolates of K. pneumoniae and P. aeruginosa and can be part of empirical therapy for treating infections caused by these bacteria.
期刊介绍：
The Iranian Journal of Microbiology (IJM) is an international, multi-disciplinary, peer-reviewed journal that provides rapid publication of the most advanced scientific research in the areas of basic and applied research on bacteria and other micro-organisms, including bacteria, viruses, yeasts, fungi, microalgae, and protozoa concerning the development of tools for diagnosis and disease control, epidemiology, antimicrobial agents, clinical microbiology, immunology, Genetics, Genomics and Molecular Biology. Contributions may be in the form of original research papers, review articles, short communications, case reports, technical reports, and letters to the Editor. Research findings must be novel and the original data must be available for review by the Editors, if necessary. Studies that are preliminary, of weak originality or merely descriptive as well as negative results are not appropriate for the journal. Papers considered for publication must be unpublished work (except in an abstract form) that is not under consideration for publication anywhere else, and all co-authors should have agreed to the submission. Manuscripts should be written in English.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
